Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesCurrent TaxesFinished GoodsGoodwillGoodwill & IntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Amphastar Pharmaceuticals (AMPH) Operating Leases: 2019-2025

Historic Operating Leases for Amphastar Pharmaceuticals (AMPH) over the last 7 years, with Sep 2025 value amounting to $39.4 million.

  • Amphastar Pharmaceuticals' Operating Leases rose 36.28% to $39.4 million in Q3 2025 from the same period last year, while for Sep 2025 it was $39.4 million, marking a year-over-year increase of 36.28%. This contributed to the annual value of $41.9 million for FY2024, which is 40.91% up from last year.
  • According to the latest figures from Q3 2025, Amphastar Pharmaceuticals' Operating Leases is $39.4 million, which was up 1.22% from $39.0 million recorded in Q2 2025.
  • Over the past 5 years, Amphastar Pharmaceuticals' Operating Leases peaked at $41.9 million during Q4 2024, and registered a low of $16.5 million during Q1 2021.
  • Over the past 3 years, Amphastar Pharmaceuticals' median Operating Leases value was $29.7 million (recorded in 2023), while the average stood at $32.4 million.
  • Its Operating Leases has fluctuated over the past 5 years, first skyrocketed by 69.00% in 2021, then dropped by 5.87% in 2023.
  • Amphastar Pharmaceuticals' Operating Leases (Quarterly) stood at $24.7 million in 2021, then dropped by 4.08% to $23.7 million in 2022, then grew by 25.44% to $29.7 million in 2023, then surged by 40.91% to $41.9 million in 2024, then spiked by 36.28% to $39.4 million in 2025.
  • Its Operating Leases stands at $39.4 million for Q3 2025, versus $39.0 million for Q2 2025 and $40.7 million for Q1 2025.